Synaptogenix rises on patent award for treating Alzheimer's

TAO Synergies

07/07/2021 14:32

** Shares of biopharmaceutical company  SNPX.O  up 5% at
$10.22 premarket 
    ** Co says it has been awarded a new patent by the U.S.
Patent and Trademark Office to treat Alzheimer's  urn:newsml:reuters.com:*:nPn9XFKRNa
    ** The patent award is for a method of inducing
synaptogenesis in a subject having synaptic loss - co
    ** The patent has potential applicability to several
candidate drugs - co's chief scientific officer
    ** Co's lead drug, Bryostatin, activates natural pathways in
the brain with potential to treat many disorders including
Alzheimer's, Parkinson's, Multiple Sclerosis and Fragile X
Mental Retardation syndrome
    ** Up to Tuesday's close, stock had gained 62% YTD

 (Reporting by Shashank Nayar in Bengaluru)
 ((Shashank.Nayar@thomsonreuters.com; within U.S. +1 646 223
8780; outside U.S. +91 80 6182 2256;))